2395 — Shin Nippon Biomedical Laboratories Income Statement
0.000.00%
Last trade - 00:00- ¥56bn
- ¥78bn
- ¥32bn
- 62
- 54
- 65
- 67
Annual income statement for Shin Nippon Biomedical Laboratories, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Yuho | Yuho | Yuho | Yuho | Tanshin |
| Standards: | JAS | JAS | JAS | JAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 15,111 | 17,748 | 25,091 | 26,450 | 32,414 |
| Cost of Revenue | |||||
| Gross Profit | 7,554 | 9,687 | 13,047 | 14,283 | 16,961 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 13,343 | 13,523 | 21,302 | 22,280 | 29,660 |
| Operating Profit | 1,767 | 4,226 | 3,789 | 4,171 | 2,754 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 4,176 | 8,183 | 7,760 | 6,974 | 6,013 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 3,678 | 7,167 | 6,051 | 5,518 | 4,865 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 3,662 | 7,128 | 6,060 | 5,531 | 4,925 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 3,662 | 7,128 | 6,060 | 5,531 | 4,925 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 77.8 | 148 | 174 | 136 | 130 |
| Dividends per Share | |||||
| Special Dividends per Share |